Clinical trials: Mild Chronic Obstructive Pulmonary Disease

Asthma, COPD

The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.

• Completed
• Age: 18 to 55 years
• Phase 2
• Pill or oral medicine
• Results posted

This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.

Trial name

NCT03858686

Testing

FP-025 capsules

Where

2 sites in Netherlands

Volunteers

27 people

Sponsor

Foresee Pharmaceuticals Co., Ltd.